-
1
-
-
70449399185
-
Topical pimecrolimus: A review of its use in the management of pediatric atopic dermatitis
-
Yang LPH, Curran MP. Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis. Pediatr Drugs 2009; 11 (6): 407-426
-
(2009)
Pediatr Drugs
, vol.11
, Issue.6
, pp. 407-426
-
-
Yang, L.P.H.1
Curran, M.P.2
-
2
-
-
33750169623
-
Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus
-
Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006; 141 (3): 199-212
-
(2006)
Int Arch Allergy Immunol
, vol.141
, Issue.3
, pp. 199-212
-
-
Stuetz, A.1
Baumann, K.2
Grassberger, M.3
-
3
-
-
0032769627
-
A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
-
Aug
-
Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999 Aug; 141 (2): 264-273
-
(1999)
Br J Dermatol
, vol.141
, Issue.2
, pp. 264-273
-
-
Grassberger, M.1
Baumruker, T.2
Enz, A.3
-
4
-
-
0036634394
-
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children: Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group
-
Jul
-
Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children: Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Pediatrics 2002 Jul; 110 (1 Pt 1): e2-9
-
(2002)
Pediatrics
, vol.110
, Issue.1 PART 1
-
-
Wahn, U.1
Bos, J.D.2
Goodfield, M.3
-
5
-
-
0036677154
-
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug: Flare Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group
-
Aug
-
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug: Flare Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group. J Allergy Clin Immunol 2002 Aug; 110 (2): 277-284
-
(2002)
J Allergy Clin Immunol
, vol.110
, Issue.2
, pp. 277-284
-
-
Kapp, A.1
Papp, K.2
Bingham, A.3
-
6
-
-
20444490896
-
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination
-
Feb
-
Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005 Feb; 52 (2): 247-253
-
(2005)
J Am Acad Dermatol
, vol.52
, Issue.2
, pp. 247-253
-
-
Papp, K.A.1
Breuer, K.2
Meurer, M.3
-
7
-
-
35348838573
-
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids
-
Nov
-
Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007 Nov; 157 (5): 954-959
-
(2007)
Br J Dermatol
, vol.157
, Issue.5
, pp. 954-959
-
-
Murrell, D.F.1
Calvieri, S.2
Ortonne, J.P.3
-
8
-
-
57649232762
-
Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis
-
Jan
-
Aschoff R, Schwanebeck U, Bräutigam M, et al. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 2009 Jan; 18 (1): 24-29
-
(2009)
Exp Dermatol
, vol.18
, Issue.1
, pp. 24-29
-
-
Aschoff, R.1
Schwanebeck, U.2
Bräutigam, M.3
-
9
-
-
65349153666
-
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis
-
May
-
Jensen J-M, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009 May; 123 (5): 1124-1133
-
(2009)
J Allergy Clin Immunol
, vol.123
, Issue.5
, pp. 1124-1133
-
-
Jensen, J.-M.1
Pfeiffer, S.2
Witt, M.3
-
10
-
-
10744229850
-
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
-
Nov
-
Allen BR, LakhanpaulM, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 Nov; 88 (11): 969-973
-
(2003)
Arch Dis Child
, vol.88
, Issue.11
, pp. 969-973
-
-
Allen, B.R.1
Lakhanpaul, M.2
Morris, A.3
-
11
-
-
33847668398
-
Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis
-
Apr
-
Eichenfield LF, Ho V, Matsunaga J, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol 2007 Apr; 34 (4): 231-236
-
(2007)
J Dermatol
, vol.34
, Issue.4
, pp. 231-236
-
-
Eichenfield, L.F.1
Ho, V.2
Matsunaga, J.3
-
12
-
-
0035034382
-
First experience of topical SDZ ASM 981 in children with atopic dermatitis
-
Apr
-
Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-787
-
(2001)
Br J Dermatol
, vol.144
, Issue.4
, pp. 781-787
-
-
Harper, J.1
Green, A.2
Scott, G.3
-
13
-
-
33645119731
-
Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%
-
Feb
-
Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 Feb; 15 (2): 138-141
-
(2006)
Exp Dermatol
, vol.15
, Issue.2
, pp. 138-141
-
-
Lakhanpaul, M.1
Davies, T.2
Allen, B.R.3
-
14
-
-
33644819775
-
Low systemic absorption and good tolerability of pimecrolimus administered as 1% cream (Elidel®) in infants with atopic dermatitis: A multicenter 3-week open-label study
-
Sep-Oct
-
Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel®) in infants with atopic dermatitis: a multicenter, 3-week, open-label study. Pediatr Dermatol 2005 Sep-Oct; 22 (5): 465-471
-
(2005)
Pediatr Dermatol
, vol.22
, Issue.5
, pp. 465-471
-
-
Staab, D.1
Pariser, D.2
Gottlieb, A.B.3
-
15
-
-
70449335541
-
-
Novartis, [online]. Available from URL:, [Accessed 2009 Oct 14]
-
Novartis. Elidel® (pimecrolimus) 1% cream: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/ pi/pdf/elidel.pdf [Accessed 2009 Oct 14]
-
Elidel® (Pimecrolimus) 1% Cream: US Prescribing Information
-
-
-
16
-
-
7944234980
-
Onset of action of pimecrolimus cream 1%in the treatment of atopic eczema in infants
-
Nov
-
Kaufmann R, Fö lster-Holst R, Hö ger P, et al. Onset of action of pimecrolimus cream 1%in the treatment of atopic eczema in infants. JAllergy Clin Immunol 2004 Nov; 114 (5): 1183-1188
-
(2004)
JAllergy Clin Immunol
, vol.114
, Issue.5
, pp. 1183-1188
-
-
Kaufmann, R.1
Fölster-Holst, R.2
Hö Ger, P.3
-
17
-
-
0036553479
-
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
-
Apr
-
Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J AmAcad Dermatol 2002 Apr; 46 (4): 495-504
-
(2002)
J AmAcad Dermatol
, vol.46
, Issue.4
, pp. 495-504
-
-
Eichenfield, L.F.1
Lucky, A.W.2
Boguniewicz, M.3
-
18
-
-
58349092742
-
The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: A randomized, controlled clinical trial
-
Feb
-
Hoeger PH, LeeK-H, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol 2009 Feb; 160 (2): 415-422
-
(2009)
Br J Dermatol
, vol.160
, Issue.2
, pp. 415-422
-
-
Hoeger, P.H.1
Leek-H Jautova, J.2
-
19
-
-
0037324145
-
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants
-
Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142 (2): 155-162
-
(2003)
J Pediatr
, vol.142
, Issue.2
, pp. 155-162
-
-
Ho, V.C.1
Gupta, A.2
Kaufmann, R.3
-
20
-
-
20844459817
-
Arandomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis
-
Oct
-
Kempers S, Boguniewicz M, Carter E, et al.Arandomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 Oct; 51 (4): 515-525
-
(2004)
J Am Acad Dermatol
, vol.51
, Issue.4
, pp. 515-525
-
-
Kempers, S.1
Boguniewicz, M.2
Carter, E.3
-
21
-
-
53749087560
-
Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis
-
Nov
-
Sigurgeirsson B, Ho V, Ferrá ndiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 2008 Nov; 22 (11): 1290-1301
-
(2008)
J Eur Acad Dermatol Venereol
, vol.22
, Issue.11
, pp. 1290-1301
-
-
Sigurgeirsson, B.1
Ho, V.2
Ferrá Ndiz, C.3
-
22
-
-
33746609359
-
Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis
-
[published erratum appears in J Dermatolog Treat 2006; 17 (4): 256]
-
Siegfried E, Korman N, Molina C, et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis [published erratum appears in J Dermatolog Treat 2006; 17 (4): 256]. J Dermatolog Treat 2006; 17 (3): 143-150
-
(2006)
J Dermatolog Treat
, vol.17
, Issue.3
, pp. 143-150
-
-
Siegfried, E.1
Korman, N.2
Molina, C.3
-
23
-
-
33645867656
-
Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice
-
NOBEL (New Online Based ELidel) Study Group
-
Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. NOBEL (New Online Based ELidel) Study Group. Am J Clin Dermatol 2006; 7 (2): 121-131
-
(2006)
Am J Clin Dermatol
, vol.7
, Issue.2
, pp. 121-131
-
-
Lübbe, J.1
Friedlander, S.F.2
Cribier, B.3
-
24
-
-
38349063398
-
Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: Results of a > 2000 patient study
-
Feb
-
Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a >2000 patient study. J Eur Acad Dermatol Venereol 2008 Feb; 22 (2): 195-203
-
(2008)
J Eur Acad Dermatol Venereol
, vol.22
, Issue.2
, pp. 195-203
-
-
Ring, J.1
Abraham, A.2
De Cuyper, C.3
-
25
-
-
33645999345
-
Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): Impact on quality of life and health-related quality of life
-
Mar
-
McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006 Mar; 20 (3): 248-254
-
(2006)
J Eur Acad Dermatol Venereol
, vol.20
, Issue.3
, pp. 248-254
-
-
McKenna, S.P.1
Whalley, D.2
De Prost, Y.3
-
26
-
-
33646838586
-
Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: Positive effects on major symptoms of atopic dermatitis and on quality of life
-
Apr
-
Sunderkö tter C, Weiss JM, Bextermö ller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. JDtsch Dermatol Ges 2006 Apr; 4 (4): 301-306
-
(2006)
JDtsch Dermatol Ges
, vol.4
, Issue.4
, pp. 301-306
-
-
Sunderkötter, C.1
Weiss, J.M.2
Bextermöller, R.3
-
27
-
-
19244366103
-
The benefit of pimecrolimus (Elidel SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis
-
Dec
-
Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002 Dec; 110 (6): 1133-1136
-
(2002)
Pediatrics
, vol.110
, Issue.6
, pp. 1133-1136
-
-
Whalley, D.1
Huels, J.2
McKenna, S.P.3
-
28
-
-
26244453293
-
Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: A multicenter, randomized trial
-
Sep
-
Staab D, Kaufmann R, Bräutigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005 Sep; 16 (6): 527-533
-
(2005)
Pediatr Allergy Immunol
, vol.16
, Issue.6
, pp. 527-533
-
-
Staab, D.1
Kaufmann, R.2
Bräutigam, M.3
-
29
-
-
49649126627
-
Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis
-
Jun 5
-
De Backer M, Morren M-A, Boonen H, et al. Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis. Dermatology 2008 Jun 5; 217 (2): 156-163
-
(2008)
Dermatology
, vol.217
, Issue.2
, pp. 156-163
-
-
De Backer, M.1
Morren, M.-A.2
Boonen, H.3
-
30
-
-
26244445627
-
Cost effectiveness of Elidel in the management of patients with atopic dermatitis in Canada
-
Nov-Dec
-
Coyle D, Barbeau M. Cost effectiveness of Elidel in the management of patients with atopic dermatitis in Canada. J CutanMed Surg 2004Nov-Dec; 8 (6): 405-410
-
(2004)
J CutanMed Surg
, vol.8
, Issue.6
, pp. 405-410
-
-
Coyle, D.1
Barbeau, M.2
-
31
-
-
33645880750
-
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age
-
Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006; 7 (2): 133-139
-
(2006)
Am J Clin Dermatol
, vol.7
, Issue.2
, pp. 133-139
-
-
Ellis, C.N.1
Kahler, K.H.2
Grueger, J.3
-
32
-
-
24944541584
-
The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: A systematic review and economic evaluation
-
Jul, xi-xiii, 1-230
-
Garside R, SteinK, Castelnuovo E, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 Jul; 9 (29): iii, xi-xiii,1-230
-
(2005)
Health Technol Assess
, vol.9
, Issue.29
-
-
Garside, R.1
Stein, K.2
Castelnuovo, E.3
-
33
-
-
33646557042
-
A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema
-
Jun
-
Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 Jun; 154 (6): 1137-1146
-
(2006)
Br J Dermatol
, vol.154
, Issue.6
, pp. 1137-1146
-
-
Pitt, M.1
Garside, R.2
Stein, K.3
-
34
-
-
0141746077
-
Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis
-
Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003; 6 (1-14): 1-14
-
(2003)
J Med Econ
, vol.6
, Issue.1-14
, pp. 1-14
-
-
Abramovits, W.1
Boguniewicz, M.2
Prendergast, M.M.3
-
35
-
-
27744525277
-
Health plan budget impact analysis for pimecrolimus
-
Jan-Feb
-
Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 2005 Jan-Feb; 11 (1): 66-73
-
(2005)
J Manag Care Pharm
, vol.11
, Issue.1
, pp. 66-73
-
-
Chang, J.1
Sung, J.2
-
36
-
-
34250712401
-
Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus
-
May
-
Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm 2007 May; 13 (4): 349-359
-
(2007)
J Manag Care Pharm
, vol.13
, Issue.4
, pp. 349-359
-
-
Delea, T.E.1
Gokhale, M.2
Makin, C.3
-
37
-
-
33644836845
-
Safety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated for up to 2 years
-
Jan
-
Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006 Jan; 117 (1): e118-28
-
(2006)
Pediatrics
, vol.117
, Issue.1
-
-
Paul, C.1
Cork, M.2
Rossi, A.B.3
-
38
-
-
37349125328
-
An update on the safety and tolerability of pimecrolimus cream 1%: Evidence from clinical trials and postmarketing surveillance
-
Langley RGB, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and postmarketing surveillance. Dermatology 2007; 215 Suppl. 1: 27-44
-
(2007)
Dermatology
, vol.215
, Issue.SUPPL. 1
, pp. 27-44
-
-
Langley, R.G.B.1
Luger, T.A.2
Cork, M.J.3
-
39
-
-
44949145270
-
Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis
-
May-Jun
-
Langley RGB, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol 2008 May-Jun; 25 (3): 301-307
-
(2008)
Pediatr Dermatol
, vol.25
, Issue.3
, pp. 301-307
-
-
Langley, R.G.B.1
Eichenfield, L.F.2
Lucky, A.W.3
-
40
-
-
20444488914
-
Long-term control of atopic dermatitis with pimecrolimus cream 1%in infants and young children: A two-year study
-
Feb
-
Papp KA, Werfel T, Fö lster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1%in infants and young children: a two-year study. J Am Acad Dermatol 2005 Feb; 52 (2): 240-246
-
(2005)
J Am Acad Dermatol
, vol.52
, Issue.2
, pp. 240-246
-
-
Papp, K.A.1
Werfel, T.2
Fölster-Holst, R.3
-
41
-
-
43649090235
-
Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease
-
Jun
-
Zuberbier T, Bräutigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008 Jun; 22 (6): 718-721
-
(2008)
J Eur Acad Dermatol Venereol
, vol.22
, Issue.6
, pp. 718-721
-
-
Zuberbier, T.1
Bräutigam, M.2
-
42
-
-
23844476199
-
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis
-
DOI 10.1159/000086739
-
Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis [publish erratum appears in Dermatology 2005; 211 (3): 292]. Dermatology 2005; 211 (2): 174-187 (Pubitemid 41160263)
-
(2005)
Dermatology
, vol.211
, Issue.2
, pp. 174-187
-
-
Hultsch, T.1
Kapp, A.2
Spergel, J.3
-
43
-
-
77952967500
-
-
February, [online]. Available from URL:, [Accessed 2009 Oct 14]
-
Hultsch T. Elidel® (pimecrolimus) cream 1%: safety update February, 2005 [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/ ac/05/slides/2005-4089s2-02-02-Novartis%20Core%20Safety%20(CS).pdf [Accessed 2009 Oct 14]
-
(2005)
Elidel® (Pimecrolimus) Cream 1%: Safety Update
-
-
Hultsch, T.1
-
44
-
-
39749187188
-
The US FDA 'black box' warning for topical calcineurin inhibitors: An ongoing controversy
-
Ring J, Mö hrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31 (3): 185-198
-
(2008)
Drug Saf
, vol.31
, Issue.3
, pp. 185-198
-
-
Ring, J.1
Möhrenschlager, M.2
Henkel, V.3
-
45
-
-
35048898681
-
Topical calcineurin inhibitors in pediatric atopic dermatitis: A critical analysis of current issues
-
Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Pediatr Drugs 2007; 9 (5): 289-299
-
(2007)
Pediatr Drugs
, vol.9
, Issue.5
, pp. 289-299
-
-
Orlow, S.J.1
-
46
-
-
33947264340
-
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
-
Apr
-
Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 Apr; 127 (4): 808-816
-
(2007)
J Invest Dermatol
, vol.127
, Issue.4
, pp. 808-816
-
-
Arellano, F.M.1
Wentworth, C.E.2
Arana, A.3
-
47
-
-
67651112009
-
Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma
-
Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219 (1): 7-21
-
(2009)
Dermatology
, vol.219
, Issue.1
, pp. 7-21
-
-
Schneeweiss, S.1
Doherty, M.2
Zhu, S.3
-
48
-
-
67349252036
-
Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom
-
May
-
Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009 May; 123 (5): 1111-1116
-
(2009)
J Allergy Clin Immunol
, vol.123
, Issue.5
, pp. 1111-1116
-
-
Arellano, F.M.1
Arana, A.2
Wentworth, C.E.3
|